Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clonal hematopoiesis in elderly twins: concordance, discordance and mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Low vs. high hemoglobin trigger for Transfusion in Vascular surgery (TV): a randomized clinical feasibility trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  1. No association between early maternal HbA1c and offspring birthweight among women without pre-existing diabetes in Greenland

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Increased risk of anemia, neutropenia and thrombocytopenia in people with HIV and well-controlled viral replication

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Blodsygdomme

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiFormidling

Vis graf over relationer

There is consensus that young patients with mantle cell lymphoma (MCL) should receive intensive immunochemotherapy regimens, but optimal treatment of elderly patients as well for as patients with limited or indolent disease is not defined. Our aim was to evaluate and compare outcome in relation to prognostic factors and first-line treatment in patients with MCL in a population-based data set. Data were collected from the Swedish and Danish Lymphoma Registries from the period of 2000 to 2011. A total of 1389 patients were diagnosed with MCL. During this period, age-standardized incidence MCL increased, most prominently among males. Furthermore, male gender was associated with inferior overall survival (OS) in multivariate analysis (hazard ratio [HR] = 1.36; P = .002). Forty-three (3.6%) patients with stage I-II disease received radiotherapy with curative intent, showing a 3-year OS of 93%. Twenty-nine (2.4%) patients followed a watch-and-wait approach and showed a 3-year OS of 79.8%. Among patients receiving systemic treatment, rituximab (n = 766; HR = 0.66; P = .001) and autologous stem cell transplant (n = 273; HR = 0.55; P = .004) were independently associated with improved OS in multivariate analysis. Hence, by a population-based approach, we were able to provide novel data on prognostic factors and primary treatment of MCL, applicable to routine clinical practice.

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind124
Udgave nummer8
Sider (fra-til)1288-95
Antal sider8
ISSN0006-4971
DOI
StatusUdgivet - 21 aug. 2014

ID: 44646729